Search Results for "1"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for 1. Results 2631 to 2640 of 2733 total matches.

Metformin for Non-Insulin-Dependent Diabetes Mellitus

   
The Medical Letter on Drugs and Therapeutics • May 12, 1995  (Issue 948)
. The Medical Letter, Inc. Phone: 1-800-211-2769 Fax: 1-914-632-1733 WEB SITE: http://www.medletter.com ...
Metformin (Glucophage - Bristol-Myers Squibb), a hypoglycemic agent, was recently marketed in the USA for oral treatment of patients with non-insulin-dependent diabetes mellitus (NIDDM) not adequately controlled by diet alone. Previously marketed in more than ninety countries, including Canada, metformin (dimethylbiguanide) is chemically related to phenformin (phenylethylbiguanide), which was withdrawn from the US market in 1976 because it caused a high incidence of lactic acidosis. In approving metformin, the US Food and Drug Administration stipulated that a post-marketing controlled...
Med Lett Drugs Ther. 1995 May 12;37(948):41-2 |  Show IntroductionHide Introduction

Neotame - a new artificial sweetener

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2002  (Issue 1137)
by addition of an N-alkyl group to yield N-[N-(3,3-dimethylbutyl)-L-α-aspartyl]-Lphenylalanine 1-methyl ester ...
Neotame (Neotame - NutraSweet Co.), an analog of aspartame (NutraSweet, and others), has been approved by the FDA for use as a nonnutritive sweetener and "flavor enhancer" in foods and beverages. Other non-caloric sweeteners available in the US include saccharin (Sweet'N Low, and others), acesulfame potassium (Sunette - Medical Letter, 1988; 30:116) and sucralose (Splenda - Medical Letter, 1998; 40:67). Neotame was approved for use in Australia and New Zealand in 2001.
Med Lett Drugs Ther. 2002 Aug 19;44(1137):73-4 |  Show IntroductionHide Introduction

Antioxidant Vitamins and Zinc for Macular Degeneration

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2003  (Issue 1158)
stages. Patients were randomized (double masked) to: (1) antioxidants at doses 5 to 15 times higher than ...
High doses of beta carotene, vitamin C, vitamin E and zinc oxide are now being promoted to the general public to "preserve eye health" (Ocuvite PreserVision), "promote retinal and visual health" (VisiVite) and "preserve healthy vision" (ICaps). Internet advertisements for these products all refer to a clinical trial, the Age-Related Eye Disease Study (AREDS), which was conducted in patients with age-related macular degeneration (AMD).
Med Lett Drugs Ther. 2003 Jun 8;45(1158):45-6 |  Show IntroductionHide Introduction

Prilosec, Nexium and Stereoisomers

   
The Medical Letter on Drugs and Therapeutics • Jun 23, 2003  (Issue 1159)
advantage (Treatment Guidelines from The Medical Letter 2002; 1:7). DEXMETHYLPHENIDATE AND METHYLPHENIDATE ...
Recently pharmaceutical manufacturers have marketed a stereoisomer of a successful drug nearing patent expiration as a new drug. Examples, such as esomeprazole (Nexium) , levalbuterol (Xopenex), escitalopram (Lexapro) and dexmethylphenidate
Med Lett Drugs Ther. 2003 Jun 23;45(1159):51-2 |  Show IntroductionHide Introduction

Pemetrexed (Alimta) for Mesothelioma

   
The Medical Letter on Drugs and Therapeutics • Apr 12, 2004  (Issue 1180)
a statistically significantly longer median survival (12.1 vs. 9.3 months), a longer time to progression (5.7 vs ...
The combination of pemetrexed (Alimta - Lilly) and cisplatin is the first chemotherapy regimen approved by the FDA for treatment of malignant pleural mesothelioma. This uncommon malignancy, which has been linked to asbestos exposure, was previously considered unresponsive to chemotherapy, with a median survival of 6-8 months from diagnosis (VW Rusch, J Clin Oncol 2003; 21:2629).
Med Lett Drugs Ther. 2004 Apr 12;46(1180):31-2 |  Show IntroductionHide Introduction

Viltolarsen (Viltepso) for Duchenne Muscular Dystrophy

   
The Medical Letter on Drugs and Therapeutics • Oct 19, 2020  (Issue 1609)
oligonucleotide golodirsen (Vyondys 53) was approved in 2019.1 Pronunciation Key Viltolarsen: vil” toe lar’ sen ...
The antisense oligonucleotide viltolarsen (Viltepso – NS Pharma) has received accelerated approval from the FDA for treatment of Duchenne muscular dystrophy (DMD) in patients who have mutations of the dystrophin gene that are amenable to exon 53 skipping (DMD-53). It is the second drug to be approved for this indication; the antisense oligonucleotide golodirsen (Vyondys 53) was approved in 2019.
Med Lett Drugs Ther. 2020 Oct 19;62(1609):167 |  Show IntroductionHide Introduction

Brella Sweat Control Patch for Primary Axillary Hyperhidrosis (online only)

   
The Medical Letter on Drugs and Therapeutics • Jul 22, 2024  (Issue 1707)
retention, and confusion) and data on its long-term efficacy and safety are lacking.1 Once-daily ...
Brella Sweat Control Patch (Candesant Biomedical), a sodium-containing transdermal patch, has been cleared by the FDA for in-office treatment of primary axillary hyperhidrosis in adults. It is the first patch to be approved in the US for this indication.
Med Lett Drugs Ther. 2024 Jul 22;66(1707):e125-6   doi:10.58347/tml.2024.1707i |  Show IntroductionHide Introduction

Adagrasib (Krazati) for Colorectal Cancer (online only)

   
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024  (Issue 1709)
fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.1 Adagrasib is the first KRAS inhibitor ...
The RAS GTPase family inhibitor adagrasib (Krazati – BMS), which received accelerated approval for treatment of KRAS G12C (glycine-to-cysteine mutation at codon 12)-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC) in 2022, has now received accelerated approval from the FDA for use with cetuximab for treatment of KRAS G12C-mutated locally advanced or metastatic colorectal cancer (CRC) in adults who received prior fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy. Adagrasib is the first KRAS inhibitor to be approved in the US for treatment...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):e137-8   doi:10.58347/tml.2024.1709f |  Show IntroductionHide Introduction

Daraxonrasib (Rasonque) for Metastatic Pancreatic Cancer

   
The Medical Letter on Drugs and Therapeutics • Sep 28, 2026  (Issue 1764)
, but response rates are low and they can cause serious toxicity.1 The European Society for Medical Oncology ...
The FDA has approved daraxonrasib (Rasonque – Revolution Medicines), an oral RAS GTPase multi-selective inhibitor, for treatment of metastatic pancreatic adenocarcinoma, regardless of RAS G12 mutation status, in adults who received at least one prior systemic therapy or are not candidates for multi-agent systemic therapy. It is the first RAS GTPase inhibitor to be approved in the US for any indication.
Med Lett Drugs Ther. 2026 Sep 28;68(1764):154-5   doi:10.58347/tml.2026.1764b |  Show IntroductionHide Introduction

Drug Interactions

   
The Medical Letter on Drugs and Therapeutics • Jun 08, 2003  (Issue 1158)
COPYRIGHT LAWS 46 SOME IMPORTANT RELATIONSHIPS BETWEEN DRUGS AND CYTOCHROME P450 (CYP) ENZYMES 1 AND P ...
Changes caused by one drug in the absorption, distribution, metabolism or excretion of another may lead to a pharmacokinetic adverse drug interaction (DN Juurlink et al, JAMA 2003; 289:1652). Additive drug interactions, such as vasodilation caused by both sildenafil (Viagra) and nitrates, can also have adverse effects.
Med Lett Drugs Ther. 2003 Jun 8;45(1158):46-8 |  Show IntroductionHide Introduction